Merus (NASDAQ:MRUS) Stock Holdings Decreased by Two Sigma Investments LP

Two Sigma Investments LP lowered its stake in shares of Merus (NASDAQ:MRUS - Free Report) by 14.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 507,741 shares of the biotechnology company's stock after selling 85,298 shares during the quarter. Two Sigma Investments LP owned 0.74% of Merus worth $21,351,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the stock. FMR LLC increased its position in shares of Merus by 0.4% during the fourth quarter. FMR LLC now owns 6,899,521 shares of the biotechnology company's stock worth $290,125,000 after acquiring an additional 25,595 shares during the period. Wellington Management Group LLP increased its position in shares of Merus by 21.1% during the fourth quarter. Wellington Management Group LLP now owns 3,497,653 shares of the biotechnology company's stock worth $147,076,000 after acquiring an additional 610,139 shares during the period. Avoro Capital Advisors LLC increased its position in shares of Merus by 56.8% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,125,000 shares of the biotechnology company's stock worth $89,356,000 after acquiring an additional 770,000 shares during the period. Boxer Capital Management LLC purchased a new stake in shares of Merus during the fourth quarter worth $79,895,000. Finally, Polar Capital Holdings Plc increased its position in shares of Merus by 34.7% during the fourth quarter. Polar Capital Holdings Plc now owns 1,706,238 shares of the biotechnology company's stock worth $71,747,000 after acquiring an additional 439,186 shares during the period. Hedge funds and other institutional investors own 96.14% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Needham & Company LLC reissued a "buy" rating and issued a $75.00 target price on shares of Merus in a report on Monday, May 19th. Wells Fargo & Company dropped their target price on Merus from $91.00 to $89.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. HC Wainwright reissued a "buy" rating and issued a $85.00 target price on shares of Merus in a report on Monday, March 3rd. Piper Sandler assumed coverage on Merus in a report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 target price on the stock. Finally, BMO Capital Markets set a $110.00 target price on Merus and gave the company an "outperform" rating in a report on Friday. Fourteen equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $86.00.

Merus Stock Performance

Shares of NASDAQ:MRUS traded down $2.19 during midday trading on Tuesday, hitting $52.96. 861,123 shares of the company's stock traded hands, compared to its average volume of 827,362. The company has a market cap of $3.67 billion, a PE ratio of -13.41 and a beta of 0.94. The firm's fifty day moving average price is $42.88 and its two-hundred day moving average price is $43.42. Merus has a twelve month low of $33.19 and a twelve month high of $61.28.

Merus (NASDAQ:MRUS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($1.40) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). The firm had revenue of $26.49 million during the quarter, compared to analyst estimates of $7.82 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. As a group, equities research analysts anticipate that Merus will post -3.85 EPS for the current fiscal year.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.